Categories Health Care, LATEST

Intuitive Surgical’s Q3 results surpass expectations

Intuitive Surgical (NASDAQ: ISRG) beat revenue and earnings expectations for the third quarter of 2019, sending the shares climbing 4.4% in aftermarket hours on Thursday.

Total revenue grew 23% year-over-year to $1.12 billion, beating estimates of $1.06 billion. The growth in revenue was driven by increased procedures and systems placements.  

Intuitive Surgical reports Q3 2019 earnings results

GAAP net income was $397 million, or $3.33 per share, compared to $293 million, or $2.45 per share, in the prior-year quarter. Adjusted net income totaled $409 million, or $3.43 per share, topping forecasts of $2.99 per share.

During the quarter, worldwide da Vinci procedures grew nearly 20% versus last year, driven mainly by growth in US general surgery procedures and worldwide urologic procedures. Intuitive shipped 275 da Vinci Surgical Systems, which was up 19% from the prior-year period, and grew its da Vinci Surgical System installed base to 5,406 systems as of quarter-end, reflecting a year-over-year increase of 12%.

Also read: Intuitive Surgical Q3 2019 Earnings Preview

Instrument and accessory revenue increased 25% year-over-year to $606 million, mainly driven by a growth in da Vinci procedure volume. Systems revenue rose by 23% to $339 million.

Intuitive ended the third quarter with $5.4 billion in cash, cash equivalents, and investments.

In August, the company acquired Scholly Fiberoptic’s robotic endoscope business, which is expected to strengthen the supply chain and increase manufacturing capacity for imaging products.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top